CONFERENCE DAY TWO
WEDNESDAY, JULY 24

7.30 Registration & Morning Coffee

8.20 Chairperson’s Opening Remarks

Harnessing the Microbiome as an Adjuvant that Improves Patient
Response to Other Cancer Therapies

Session Purpose:
Whilst immune checkpoint inhibitors (ICIs) gave the role of the microbiome in cancer therapy response the spotlight, investigating the role of the microbiome in this context surpasses the checkpoint era. This theme explores monotherapy and combination therapeutic strategies that involve priming the microbiome to enhance or modulate patient response to other cancer therapies.

8.30

Outlining Enterome’s Onco-Mimics Program: Microbiome- Derived Immunotherapy for Treatment of Cancers

• Clarifying how targeting novel antigens called onco-mimics can induce cytotoxic T-cell response against tumors in combination with checkpoint inhibitors
• Understanding how EO2401 can be used in patients with Glioblastoma Multiforme (GBM)

Christophe Bonny
Chief Scientific Officer
Enterome Biosciences

 

9.00

Developing Live Biotherapeutics to Target Immuno-Oncology

• Discussing how LBPs offer a novel approach to immuno-oncology in monotherapy and combination settings
• Addressing how MRx0518 inhibits tumour growth in multiple preclinical models, affects tumour immune populations and has a strong immunostimulatory profile
• Pinpointing mode of action: TLR5-mediated immune activation via bacterial flagellin

Imke Mulder
Director of Research
4D Pharma

9.30

Discovering the Role of Microbiome Modulation in Treating PD-1 Non-Responders in Melanoma

• Learning how intestinal dysbiosis is linked with adverse outcomes to PD-1 blockade in melanoma and other cancers
• Outlining the clinical trials attempting to target intestinal dysbiosis are ongoing in melanoma and other cancers
• Evaluating whole fecal microbiome transplantation for proof of concept in PD-1 refractory disease

Diwakar Davar, MD
Assistant Professor of Medicine
University of Pittsburgh

 

 

 

10.00

Revealing the Effects of the Microbiome on Response to Cancer Immunotherapy

• Recognizing that pre-clinical models are critical components towards mechanistic understanding of the role of microbiome
• Building internal clinical-relevant preclinical models to seek for the underlying biology
• Applying the systems biology approach to investigate novel approaches to augment host responses to cancer immunotherapy

Xue Liang
Senior Scientist, Microbiome/ Molecular Discovery
Merck Exploratory Science Center

10.30 Speed Networking & Morning Refreshments

11.00

Leveraging Second Genome’s Platform to Develop Microbiome-Derived Cancer Immunotherapy

• Applying cross-cohort meta-analysis to identify critical microbial signatures associated with anti-PD-1 response
• Identifying microbial bioactives from anti-PD-1 responder signatures to test for ability to modulate immune function, in vitro and in vivo
• Developing therapeutic peptides and proteins that promote anti-tumor immunity for cancer immunotherapeutics

Helena Kiefel 
Senior Scientist
Second Genome

 

11.30

Improving Cancer Treatment Through Oncobax-Based Therapeutics

• Discovering how intestinal commensals dictate our systemic and anticancer immunity
• Harnessing the microbiome for the discovery of diagnosis and understanding why therapeutic tools in cancer are key for modulating the clinical outcome of anticancer regimens
• Developing Oncobax-based therapeutics to improve the efficacy of anticancer treatments

Romain Daillère
Head of Preclinical Research & Co- Founder
EverImmune

 

Putting the Spotlight on Phage Therapy Approaches in Cancer

Session Purpose:
An increasing body of research has highlighted the renaissance of phage therapy as a therapeutic class with huge clinical potential in cancer patients. The purpose of this theme is to showcase the mechanistic pathways of phage therapy and its application as a cancer therapeutic.

12.00

Utilizing Customized Phages to Treat Bacteria-Associated Colorectal Cancer

• Showcasing a growing body of evidence that the presence of F. nucleatum bacteria within colorectal tumours promotes tumour growth and resistance to cancer therapeutics
• Developing a novel phage therapy of engineered phage for targeted eradication of F. nucleatum
• Providing better treatment care for CRC patients through conventional therapeutics in combination with customized phage therapies

Maya Kahan-Hanum
CRC Project Leader
BiomX

12.30 Lunch & Networking

Integrating Microbiome-Based Approaches into Routine Oncology Practice

Session Purpose:
It is vital to address where we stand with current microbiome-oncology research and innovation efforts.
The purpose of this theme will be to discuss how this field will evolve in the near future as microbiome
considerations are integrated into cancer drug development strategies and routine oncology medical practice

13.30

Panel Discussion: Where do we Stand with Current Innovation & Future Integration of Microbiome-Based Approaches into Routine Oncology Practice?

• What are physicians concerned about when considering microbiome-based approaches in cancer care, and how can these concerns be addressed?
• What is the biggest bottleneck in achieving success with microbiome-based approaches in the oncology space?
• Having discussed the various applications of the microbiome in cancer over the past two days (1 - LBP as an adjuvant for improved safety, 2 - for improved efficacy, 3 – as a patient stratification factor), which application will be most impactful in the short and long term?
• If we weren’t cost-limited, how could we accelerate microbiome-based LBPs to the cancer drug market?
• What would we like to know about large pharma’s assessment of the potential of the microbiome in cancer?

Fyza Shaikh, MD
Postdoctoral Fellow
John Hopkins Hospital

Daniel van der Lelie
Chief Scientific Officer
Gusto Global

Matthew Henn
Executive VP, Chief Scientific Officer
Seres Therapeutics

Breakout Roundtables

Session Purpose:
A holistic understanding of infrastructure requirements is needed to realize the full potential of the various applications of the microbiome in cancer care. This session will facilitate open discussion amongst participants in an informal setting. After splitting into groups, participants with have the opportunity to discuss one of the following questions:

Oncology breakout sessions

15.00 Chairperson’s Closing Remarks

15.10 End of the 1st Microbiome Movement – Oncology Response Summit